BACKGROUND: Adipose tissue secretory proteins, called adipokines, play pivotal roles in the pathophysiology of obesity and its associated disorders such as metabolic syndrome, type 2 diabetes, and cardiovascular disease. Because methods for comprehensive adipokine profiling in patient plasma and other biological samples are currently limited, we developed a multiplex immunoassay for rapid and high-throughput measurement of 25 adipokines in only 50 microL of sample. METHODS: (Pre)adipocyte and ex vivo cultured adipose tissue supernatants were generated and together with plasma from 5 morbidly obese patients and 5 healthy and normal weight controls used to develop the adipokine multiplex immunoassay and test its usefulness in biological samples. We assessed adipokine dynamic ranges, lower limits of detection and quantification, cross-reactivity, intra- and interassay variation, and correlation with adipokine ELISAs. RESULTS: The limits of quantification and broad dynamic ranges enabled measurement of all 25 adipokines in supernatants and patient plasmas, with the exception of TNF-alpha in plasma samples. Intraassay variation was <10% for all adipokines; interassay variation was < 15%. The multiplex immunoassay results correlated significantly with ELISA measurements. Plasma adipokine profiling showed significantly higher concentrations of the novel adipokines cathepsin S (5.1 x 10(4) vs 4.3 x 10(4) ng/L, P = 0.003) and chemerin (4.1 x 10(5) vs 2.7 x 10(5) ng/L, P = 0.0008) in morbidly obese patients than normal weight controls, besides the established differences in adiponectin and leptin concentrations. CONCLUSIONS: Our findings underscore the relevance of the novel adipokines cathepsin S and chemerin, but foremost the potential of this novel method for both comprehensive adipokine profiling in large patient cohorts and for biological discovery.
BACKGROUND: Adipose tissue secretory proteins, called adipokines, play pivotal roles in the pathophysiology of obesity and its associated disorders such as metabolic syndrome, type 2 diabetes, and cardiovascular disease. Because methods for comprehensive adipokine profiling in patient plasma and other biological samples are currently limited, we developed a multiplex immunoassay for rapid and high-throughput measurement of 25 adipokines in only 50 microL of sample. METHODS: (Pre)adipocyte and ex vivo cultured adipose tissue supernatants were generated and together with plasma from 5 morbidly obesepatients and 5 healthy and normal weight controls used to develop the adipokine multiplex immunoassay and test its usefulness in biological samples. We assessed adipokine dynamic ranges, lower limits of detection and quantification, cross-reactivity, intra- and interassay variation, and correlation with adipokine ELISAs. RESULTS: The limits of quantification and broad dynamic ranges enabled measurement of all 25 adipokines in supernatants and patient plasmas, with the exception of TNF-alpha in plasma samples. Intraassay variation was <10% for all adipokines; interassay variation was < 15%. The multiplex immunoassay results correlated significantly with ELISA measurements. Plasma adipokine profiling showed significantly higher concentrations of the novel adipokines cathepsin S (5.1 x 10(4) vs 4.3 x 10(4) ng/L, P = 0.003) and chemerin (4.1 x 10(5) vs 2.7 x 10(5) ng/L, P = 0.0008) in morbidly obesepatients than normal weight controls, besides the established differences in adiponectin and leptin concentrations. CONCLUSIONS: Our findings underscore the relevance of the novel adipokines cathepsin S and chemerin, but foremost the potential of this novel method for both comprehensive adipokine profiling in large patient cohorts and for biological discovery.
Authors: H S Schipper; R Nuboer; S Prop; H J van den Ham; F K de Boer; Ç Kesmir; I M H Mombers; K A van Bekkum; J Woudstra; J H Kieft; I E Hoefer; W de Jager; B Prakken; M van Summeren; E Kalkhoven Journal: Diabetologia Date: 2012-07-18 Impact factor: 10.122
Authors: Jan Westerink; Gideon R Hajer; Mariëtte E G Kranendonk; Henk S Schipper; Houshang Monajemi; Eric Kalkhoven; Frank L J Visseren Journal: Lipids Date: 2014-01-21 Impact factor: 1.880
Authors: Consuelo Treviño-Garza; Leonardo Mancillas-Adame; Cynthia M Estrada-Zúñiga; Jesús Z Villarreal-Pérez; Laura Villarreal-Martinez; Manuel E De la O-Cavazos Journal: J Clin Lab Anal Date: 2015-03-26 Impact factor: 2.352
Authors: M Reyman; A A Verrijn Stuart; M van Summeren; M Rakhshandehroo; R Nuboer; F K de Boer; H J van den Ham; E Kalkhoven; B Prakken; H S Schipper Journal: Int J Obes (Lond) Date: 2013-05-20 Impact factor: 5.095
Authors: R Klaasen; M M J Herenius; C A Wijbrandts; W de Jager; L H van Tuyl; M T Nurmohamed; B J Prakken; D M Gerlag; P P Tak Journal: Ann Rheum Dis Date: 2012-03-22 Impact factor: 19.103
Authors: Freek G Bouwman; Baukje de Roos; Isabel Rubio-Aliaga; L Katie Crosley; Susan J Duthie; Claus Mayer; Graham Horgan; Abigael C Polley; Carolin Heim; Susan L M Coort; Chris T Evelo; Francis Mulholland; Ian T Johnson; Ruan M Elliott; Hannelore Daniel; Edwin C M Mariman Journal: BMC Med Genomics Date: 2011-03-25 Impact factor: 3.063